EveryLife submitted comments to inform the FDA on the Patient-Focused Drug Development Guidance July 14, 2023 Share this page Comments to inform the U.S. Food and Drug Administration on the “Patient-Focused Drug Development Guidance 4: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making”. Patient-Focused Drug Development (PFDD) Related Articles The EveryLife Foundation Submits Comments to Support Patient-Focused Drug Development and Medical Innovation July 01, 2026 The EveryLife Foundation Submits Comments on the Impacts of PFDD Meetings July 01, 2026 FDA Rare Disease Roundtable – June 3, 2026 June 04, 2026 See All News